Lipids & metabolic liver disease
Antidiabetic and lipid‐lowering medication use inversely linked with serum biomarkers of liver fibrosis
Authors' conclusion
Antidiabetic and lipid-lowering medication use was associated with lower serum liver fibrosis biomarkers. Among participants with European ancestry, associations between combined use of these medications and lower FIB-4 or APRI scores were stronger in those at high genetic risk of MASH. Longitudinal studies are warranted to extend upon these potentially clinically important findings.
Study context
- Population
- Participants of two phase 3 trials of MASH with bridging fibrosis or compensated cirrhosisor compensated cirrhosis 864
- Participants
- 1,649 participants2 phase 3 trials
- Exposure
- Combined antidiabetic and lipid-lowering medication use vs nonuse
- Outcome
- Serum liver fibrosis biomarkers (APRI, ELF, FIB-4, FibroSure/FibroTest), least-squares means
- Follow-up
- Baseline
Methodological detailsbaseline data from two phase 3 trials, multivariable linear regression
- Baseline data from two phase 3 trials
- Multivariable linear regression
Main finding
As reported in the abstract
Adjusted mean serum fibrosis biomarkers
Combined use vs NonuseEstimate (95% CI)
- 3.2%; lower with combined use
difference in adjusted mean ELF −0.34(−0.47 to −0.20)
- 18.0%; lower with combined use
difference in adjusted mean FIB-4 −0.53(−0.74 to −0.32)
- 23.1%; lower with combined use
difference in adjusted mean APRI −0.27(−0.37 to −0.18)
- 14.7%; lower with combined use
difference in adjusted mean FibroSure/FibroTest −0.08(−0.11 to −0.06)
Observational data: associations, not effects.
Further findings
Interaction with MASH weighted polygenic risk score (wPRS) (high >median vs low ≤median), European ancestry (N = 742)
- Inverse association for FIB-4 stronger with high vs low wPRS
- interaction p = 0.01
- Inverse association for APRI stronger with high vs low wPRS
- interaction p = 0.004
- No significant interactions for ELF or FibroSure/FibroTest
Original publication
Antidiabetic and lipid‐lowering medication use inversely linked with serum biomarkers of liver fibrosis. Diabetes Obes Metab. Published 15 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →